NCT06298565 A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
| NCT ID | NCT06298565 |
| Status | Recruiting |
| Phase | — |
| Sponsor | argenx |
| Condition | Myasthenia Gravis |
| Study Type | OBSERVATIONAL |
| Enrollment | 680 participants |
| Start Date | 2024-11-04 |
| Primary Completion | 2034-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 680 participants in total. It began in 2024-11-04 with a primary completion date of 2034-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a non-interventional, prospective, post authorization safety study. Patients with gMG who are expected to start treatment with efgartigimod at enrolment or are within their first cycle of efgartigimod at enrolment will be eligible to enroll into the efgartigimod cohort. Patients with gMG who have not been exposed to efgartigimod and for whom it is not planned to start treatment with efgartigimod at enrolment will be eligible to enroll into the non-efgartigimod cohort.
Eligibility Criteria
Inclusion Criteria: * Patients diagnosed with gMG who are expected to start commercial efgartigimod at enrolment or who are within their first cycle of efgartigimod at enrolment or Patients diagnosed with gMG who have not been exposed to efgartigimod and for whom it is not planned to start treatment with efgartigimod at enrolment * Have provided appropriate written informed consent Exclusion Criteria: * None
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06298565 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Myasthenia Gravis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06298565 currently recruiting?
Yes, NCT06298565 is actively recruiting participants. Contact the research team at Clinicaltrials@argenx.com for enrollment information.
Where is the NCT06298565 trial being conducted?
This trial is being conducted at San Francisco, United States, Boca Raton, United States, Jacksonville Beach, United States, Port Charlotte, United States and 11 additional locations.
Who is sponsoring the NCT06298565 clinical trial?
NCT06298565 is sponsored by argenx. The trial plans to enroll 680 participants.